Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biologics Contract Manufacturing Market

4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biologics Contract Manufacturing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Biologics Contract Manufacturing: Overview
5.2. Trends in Biopharma Contract Manufacturing
5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.4. COVID-19 Pandemic Impact on Industry

6. Global Biologics Contract Manufacturing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value & Volume Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Molecular Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type

7. Global Biologics Contract Manufacturing Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value & Volume Forecast, by Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Country/Region

8. North America Biologics Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value & Volume Forecast, by Type, 2017–2031
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.2.3. Vaccines
8.2.4. Molecular Therapy
8.2.5. Others
8.3. Market Value & Volume Forecast, by Country, 2017–2031
8.3.1. U.S.
8.3.2. Canada
8.4. Market Attractiveness Analysis
8.4.1. By Type
8.4.2. By Country

9. Europe Biologics Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value & Volume Forecast, by Type, 2017–2031
9.2.1. Monoclonal Antibodies
9.2.2. Recombinant Proteins
9.2.3. Vaccines
9.2.4. Molecular Therapy
9.2.5. Others
9.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Market Attractiveness Analysis
9.4.1. By Type
9.4.2. By Country/Sub-region

10. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Molecular Therapy
10.2.5. Others
10.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia & New Zealand
10.3.5. Rest of Asia Pacific
10.4. Market Attractiveness Analysis
10.4.1. By Type
10.4.2. By Country/Sub-region

11. Latin America Biologics Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Molecular Therapy
11.2.5. Others
11.3. Market Value & Volume Forecast, by Country//Sub-region, 2017–2031
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Market Attractiveness Analysis
11.4.1. By Type
11.4.2. By Country/Sub-region

12. Middle East & Africa Biologics Contract Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Molecular Therapy
12.2.5. Others
12.3. Market Value & Volume Forecast, by Country/Sub-region, 2017–2031
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Rest of Middle East & Africa
12.4. Market Attractiveness Analysis
12.4.1. By Type
12.4.2. By Country/Sub-region

13. Competition Landscape
13.1. Company Profiles
13.1.1. Lonza Group
13.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.1.2. Product Portfolio
13.1.1.3. SWOT Analysis
13.1.1.4. Strategic Overview
13.1.2. Samsung Biologics Co., Ltd.
13.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.2.2. Product Portfolio
13.1.2.3. SWOT Analysis
13.1.2.4. Strategic Overview
13.1.3. Patheon by Thermo Fisher Scientific, Inc.
13.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.3.2. Product Portfolio
13.1.3.2. SWOT Analysis
13.1.3.3. Strategic Overview
13.1.4. Cambrex Corporation
13.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.4.2. Product Portfolio
13.1.4.3. SWOT Analysis
13.1.4.4. Strategic Overview
13.1.5. Siegfried Holding AG
13.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.5.2. Product Portfolio
13.1.5.3. SWOT Analysis
13.1.5.4. Strategic Overview
13.1.6. Fujifilm Holding Corporation
13.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.6.2. Product Portfolio
13.1.6.3. SWOT Analysis
13.1.6.4. Strategic Overview
13.1.7. AbbVie, Inc.
13.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.7.2. Product Portfolio
13.1.7.3. SWOT Analysis
13.1.7.4. Strategic Overview
13.1.8. Boehringer Ingelheim
13.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.8.2. Product Portfolio
13.1.8.3. SWOT Analysis
13.1.8.4. Strategic Overview
13.1.9. Recipharm Pharmaceuticals
13.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.9.2. Product Portfolio
13.1.9.3. SWOT Analysis
13.1.9.4. Strategic Overview
13.1.10. WuXi Biologics
13.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.10.2. Product Portfolio
13.1.10.3. SWOT Analysis
13.1.10.4. Strategic Overview
13.1.11. Catalent, Inc.
13.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.1.11.2. Product Portfolio
13.1.11.3. SWOT Analysis
13.1.11.4. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Biologics Contract Manufacturing Market Value Share, by Type, 2020

Figure 03: Biologics Contract Manufacturing Market Value Share, by Region, 2020

Figure 04: Global Biologics Contract Manufacturing Market Value Share Analysis, by Type, 2020 and 2031

Figure 05: Global Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 06: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Monoclonal Antibodies, 2017?2031

Figure 07: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Recombinant Proteins, 2017?2031

Figure 08: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Vaccines, 2017?2031

Figure 09: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Molecular Therapy, 2017?2031

Figure 10: Global Biologics Contract Manufacturing Market Value (US$ Mn), by Others, 2017–2031

Figure 11: Global Biologics Contract Manufacturing Market Value Share Analysis, by Region, 2020 and 2031

Figure 12: Global Biologics Contract Manufacturing Market Attractiveness Analysis, by Region, 2021–2031

Figure 13: North America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 14: North America Biologics Contract Manufacturing Market Value Share Analysis, by Country, 2020 and 2031

Figure 15: North America Biologics Contract Manufacturing Market Attractiveness Analysis, by Country, 2021–2031

Figure 16: North America Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 17: North America Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 18: Europe Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 19: Europe Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 20: Europe Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 21: Europe Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 22: Europe Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 23: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 24: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 25: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 26: Asia Pacific Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 27: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 28: Latin America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: Latin America Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 30: Latin America Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

Figure 31: Latin America Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 32: Latin America Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 33: Middle East & Africa Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 34: Middle East & Africa Biologics Contract Manufacturing Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 35: Middle East & Africa Biologics Contract Manufacturing Market Attractiveness Analysis, by Country/Sub-Region, 2021–2031

Figure 36: Middle East & Africa Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 37: Middle East & Africa Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

List of Tables

List of Tables

Table 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2031

Table 02: Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 03: North America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 04: North America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 05: Europe Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 06: Europe Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 07: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 08: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: Latin America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 10: Latin America Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 11: Middle East & Africa Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 12: Middle East & Africa Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031